Yahoo · Nov 7, 2026
Why Embecta Bears Were Right Before A 54% Drop
If you had paused on Embecta in late 2025, wondering whether steady diabetes-device cash flows and analyst price targets justified a position, the past year has delivered a harsh answer. Investors who held Embecta over the past year are down 53.6%, including dividends. With lawsuits now alleging misleading guidance and weak pen needle demand, the real question is which assumptions about earnings visibility and product resilience were already sitting in plain sight back on 6 November...

